149 related articles for article (PubMed ID: 36038734)
21. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
[TBL] [Abstract][Full Text] [Related]
22. Role of progesterone in endometrial cancer.
Kim JJ; Chapman-Davis E
Semin Reprod Med; 2010 Jan; 28(1):81-90. PubMed ID: 20104432
[TBL] [Abstract][Full Text] [Related]
23. Up-regulation of nuclear receptor corepressor (NCoR) in progestin-induced growth suppression of endometrial hyperplasia and carcinoma.
Kashima H; Horiuchi A; Uchikawa J; Miyamoto T; Suzuki A; Ashida T; Konishi I; Shiozawa T
Anticancer Res; 2009 Apr; 29(4):1023-9. PubMed ID: 19414341
[TBL] [Abstract][Full Text] [Related]
24. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
Gong Q; Chen X; Xie X
Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
[TBL] [Abstract][Full Text] [Related]
25. PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis.
Travaglino A; Raffone A; Saccone G; Insabato L; Mollo A; De Placido G; Zullo F
Eur J Obstet Gynecol Reprod Biol; 2018 Dec; 231():104-110. PubMed ID: 30342311
[TBL] [Abstract][Full Text] [Related]
26. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation.
Dai D; Kumar NS; Wolf DM; Leslie KK
Am J Obstet Gynecol; 2001 Apr; 184(5):790-7. PubMed ID: 11303185
[TBL] [Abstract][Full Text] [Related]
27. Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Zhang H; Yan L; Bai Y; Li C; Guo Q; Wang C; Zhao X; Li M
Gynecol Oncol; 2015 Mar; 136(3):549-53. PubMed ID: 25451692
[TBL] [Abstract][Full Text] [Related]
28. ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by targeting MGLL.
Ma X; Xia M; Wei L; Guo K; Sun R; Liu Y; Qiu C; Jiang J
Cell Death Dis; 2022 Dec; 13(12):1067. PubMed ID: 36550099
[TBL] [Abstract][Full Text] [Related]
29. Fertility preserving management of early endometrial cancer in a patient cohort at the department of women's health at the university of Tuebingen.
Andress J; Pasternak J; Walter C; Kommoss S; Krämer B; Hartkopf A; Brucker SY; Schönfisch B; Steinmacher S
Arch Gynecol Obstet; 2021 Jul; 304(1):215-221. PubMed ID: 33606091
[TBL] [Abstract][Full Text] [Related]
30. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
Gu C; Zhang Z; Yu Y; Liu Y; Zhao F; Yin L; Feng Y; Chen X
Cancer Sci; 2011 Mar; 102(3):557-64. PubMed ID: 21205080
[TBL] [Abstract][Full Text] [Related]
31. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
32. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
[TBL] [Abstract][Full Text] [Related]
33. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer.
Cholakian D; Hacker K; Fader AN; Gehrig PA; Tanner EJ
Gynecol Oncol; 2016 Feb; 140(2):234-8. PubMed ID: 26706662
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia.
Amezcua CA; Zheng W; Muderspach LI; Felix JC
Gynecol Oncol; 1999 Apr; 73(1):126-36. PubMed ID: 10094893
[TBL] [Abstract][Full Text] [Related]
35. Fertility-Sparing Management Using Progestin for Young Women with Endometrial Cancer From a Population-Based Study.
Kim SR; van der Zanden C; Ikiz H; Kuzelijevic B; Havelock J; Kwon JS
J Obstet Gynaecol Can; 2018 Mar; 40(3):328-333. PubMed ID: 28986185
[TBL] [Abstract][Full Text] [Related]
36. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
[TBL] [Abstract][Full Text] [Related]
37. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
[TBL] [Abstract][Full Text] [Related]
38. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.
Gadducci A; Spirito N; Baroni E; Tana R; Genazzani AR
Gynecol Endocrinol; 2009 Oct; 25(10):683-91. PubMed ID: 19562604
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
Zhou R; Yang Y; Lu Q; Wang J; Miao Y; Wang S; Wang Z; Zhao C; Wei L
Gynecol Oncol; 2015 Dec; 139(3):424-8. PubMed ID: 26428941
[TBL] [Abstract][Full Text] [Related]
40. Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review).
Banno K; Kisu I; Yanokura M; Tsuji K; Masuda K; Ueki A; Kobayashi Y; Yamagami W; Nomura H; Susumu N; Aoki D
Int J Oncol; 2012 Jun; 40(6):1755-62. PubMed ID: 22366992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
